GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
257
c/tirzepatide·posted 21 days ago by u/laila_wikstrom

[Trial Data] SURMOUNT-4 withdrawal arm is the scariest chart in this space

Trial Data Receipts ×4

SURMOUNT-4 withdrawal arm is the scariest chart in this space. It is the sort of thing everyone half-believes and nobody writes down.

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.

If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.

265 up / 8 down97% upvoted19 commentsid piebtu8 Jul 2026

19 comments

15 in this archive, depth 4

best — the order this archive was captured in

u/nz_unfunded27 points·19 days ago·edited

Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.

replysharereportpermalink
u/ferran_mensah12 points·19 days ago

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

replysharereportpermalink
u/nz_unfunded3 points·19 days ago

hold the dose that works, the ladder is not a leaderboard

replysharereportpermalink
u/ingrid_correia22 points·19 days ago

Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.

replysharereportpermalink
u/halima_boateng15 points·19 days ago

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

replysharereportpermalink
u/laila_wikstromOP32 points·19 days ago

Went 10 to 12.5 on the calendar and had the worst fortnight of the whole run. Dropped back to 10 and everything settled.

replysharereportpermalink
u/aurel_lindqvist14 points·20 days ago

switching from sema is not a dose conversion, there is no clean equivalence

replysharereportpermalink
u/britt_okwuosa9 points·19 days ago·edited

Same experience with the appetite effect being flatter across the week rather than front-loaded.

replysharereportpermalink
u/gentle_correctionnice about it4 points·19 days ago

sulphur burps are the signature complaint and they are not dangerous

replysharereportpermalink
u/hugo_bergstrom3 points·19 days ago

sulphur burps are the signature complaint and they are not dangerous

gentle_correction is right that the two molecules are not interchangeable. There is no published conversion and the ones circulating are invented.

replysharereportpermalink
u/nabila_ogunleye9 points·19 days ago

Correction to my own post above — I said 12.5mg and I have been on 10mg since the spring. Same argument, wrong number.

replysharereportpermalink
u/cato_girard15 points·20 days ago

dual agonist, so the GIP arm is doing something the sema threads will not tell you about

replysharereportpermalink
u/bastian_ekstrom9 points·21 days ago

The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.

replysharereportpermalink
u/halima_boateng0 points·20 days ago

The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.

Saving this one. It is the clearest statement of the stall problem I have read here.

replysharereportpermalink
u/sanne_novak1 point·20 days ago

Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.